181 related articles for article (PubMed ID: 22326863)
1. Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcome.
Wang Y; Li S; Chen L; You G; Bao Z; Yan W; Shi Z; Chen Y; Yao K; Zhang W; Kang C; Jiang T
Neuro Oncol; 2012 Apr; 14(4):518-25. PubMed ID: 22326863
[TBL] [Abstract][Full Text] [Related]
2. Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma.
Laxton RC; Popov S; Doey L; Jury A; Bhangoo R; Gullan R; Chandler C; Brazil L; Sadler G; Beaney R; Sibtain N; King A; Bodi I; Jones C; Ashkan K; Al-Sarraj S
Neuro Oncol; 2013 Dec; 15(12):1635-43. PubMed ID: 24158110
[TBL] [Abstract][Full Text] [Related]
3. Short-term survivors in glioblastomas with oligodendroglioma component: a clinical study of 186 Chinese patients from a single institution.
Jiang H; Ren X; Wang J; Zhang Z; Jia W; Lin S
J Neurooncol; 2014 Jan; 116(2):395-404. PubMed ID: 24264532
[TBL] [Abstract][Full Text] [Related]
4. Glioblastoma with oligodendroglial component represents a subgroup of glioblastoma with high prevalence of IDH1 mutation and association with younger age.
Ha SY; Kang SY; Do IG; Suh YL
J Neurooncol; 2013 May; 112(3):439-48. PubMed ID: 23412777
[TBL] [Abstract][Full Text] [Related]
5. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China.
Li S; Yan C; Huang L; Qiu X; Wang Z; Jiang T
Neuro Oncol; 2012 Jan; 14(1):109-16. PubMed ID: 22039037
[TBL] [Abstract][Full Text] [Related]
6. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
van den Bent MJ; Dubbink HJ; Marie Y; Brandes AA; Taphoorn MJ; Wesseling P; Frenay M; Tijssen CC; Lacombe D; Idbaih A; van Marion R; Kros JM; Dinjens WN; Gorlia T; Sanson M
Clin Cancer Res; 2010 Mar; 16(5):1597-604. PubMed ID: 20160062
[TBL] [Abstract][Full Text] [Related]
7. Pediatric glioblastoma with oligodendroglioma component: aggressive clinical phenotype with distinct molecular characteristics.
Mizoguchi M; Hata N; Suzuki SO; Fujioka Y; Murata H; Amano T; Nakamizo A; Yoshimoto K; Iwaki T; Sasaki T
Neuropathology; 2013 Dec; 33(6):652-7. PubMed ID: 23530875
[TBL] [Abstract][Full Text] [Related]
8. Glioblastoma with oligodendroglioma component (GBM-O): molecular genetic and clinical characteristics.
Appin CL; Gao J; Chisolm C; Torian M; Alexis D; Vincentelli C; Schniederjan MJ; Hadjipanayis C; Olson JJ; Hunter S; Hao C; Brat DJ
Brain Pathol; 2013 Jul; 23(4):454-61. PubMed ID: 23289977
[TBL] [Abstract][Full Text] [Related]
9. IDH1 mutation of gliomas with long-term survival analysis.
Myung JK; Cho HJ; Park CK; Kim SK; Phi JH; Park SH
Oncol Rep; 2012 Nov; 28(5):1639-44. PubMed ID: 22922798
[TBL] [Abstract][Full Text] [Related]
10. A new der(1;7)(q10;p10) leading to a singular 1p loss in a case of glioblastoma with oligodendroglioma component.
Gadji M; Crous-Tsanaclis AM; Mathieu D; Mai S; Fortin D; Drouin R
Neuropathology; 2014 Apr; 34(2):170-8. PubMed ID: 24118308
[TBL] [Abstract][Full Text] [Related]
11. Differential molecular genetic analysis in glioblastoma multiforme of long- and short-term survivors: a clinical study in Chinese patients.
Zhang GB; Cui XL; Sui DL; Ren XH; Zhang Z; Wang ZC; Lin S
J Neurooncol; 2013 Jun; 113(2):251-8. PubMed ID: 23494873
[TBL] [Abstract][Full Text] [Related]
12. The clinical characteristics and prognostic factors of multiple lesions in glioblastomas.
Tunthanathip T; Sangkhathat S; Tanvejsilp P; Kanjanapradit K
Clin Neurol Neurosurg; 2020 Aug; 195():105891. PubMed ID: 32480195
[TBL] [Abstract][Full Text] [Related]
13. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.
van den Bent MJ; Dubbink HJ; Sanson M; van der Lee-Haarloo CR; Hegi M; Jeuken JW; Ibdaih A; Brandes AA; Taphoorn MJ; Frenay M; Lacombe D; Gorlia T; Dinjens WN; Kros JM
J Clin Oncol; 2009 Dec; 27(35):5881-6. PubMed ID: 19901104
[TBL] [Abstract][Full Text] [Related]
14. Prognosis of Glioblastoma With Oligodendroglioma Component is Associated With the IDH1 Mutation and MGMT Methylation Status.
Myung JK; Cho HJ; Kim H; Park CK; Lee SH; Choi SH; Park P; Yoon JM; Park SH
Transl Oncol; 2014 Dec; 7(6):712-9. PubMed ID: 25500080
[TBL] [Abstract][Full Text] [Related]
15. Loss of 5-hydroxymethylcytosine and intratumoral heterogeneity as an epigenomic hallmark of glioblastoma.
Kraus TF; Kolck G; Greiner A; Schierl K; Guibourt V; Kretzschmar HA
Tumour Biol; 2015 Nov; 36(11):8439-46. PubMed ID: 26022161
[TBL] [Abstract][Full Text] [Related]
16. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
[TBL] [Abstract][Full Text] [Related]
17. Molecular profile of oligodendrogliomas in young patients.
Suri V; Jha P; Agarwal S; Pathak P; Sharma MC; Sharma V; Shukla S; Somasundaram K; Mahapatra AK; Kale SS; Sarkar C
Neuro Oncol; 2011 Oct; 13(10):1099-106. PubMed ID: 21937591
[TBL] [Abstract][Full Text] [Related]
18. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors.
Gan HK; Rosenthal MA; Dowling A; Kalnins R; Algar E; Wong N; Benson A; Woods AM; Cher L
Neuro Oncol; 2010 May; 12(5):500-7. PubMed ID: 20406900
[TBL] [Abstract][Full Text] [Related]
20. Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas.
Xiong J; Liu Y; Wang Y; Ke RH; Mao Y; Ye ZR
Chin Med J (Engl); 2010 Dec; 123(24):3566-73. PubMed ID: 22166632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
